Table 3.
months (median) | 95 % CI | p-value | ||||
---|---|---|---|---|---|---|
Follow-up | 16.14 | |||||
Overall survival | ||||||
from first diagnosis | 127.9 | 87.1- 168.7 | ||||
from first diagnosis liver metastases | 56.3 | 44.5 - 67.9 | ||||
from first interventional treatment | 21.9 | 11.1 - 32.6 | ||||
Maximum diameter of liver metastases (≥ vs. < 3.9 cm) | 16.1 | 38.7 | 9.8 - 22.5 | 19.6 - 57.8 | 0.001 | |
Best response overall (OR, RECIST) | ||||||
OR (CR + PR) (n = 37) vs. PD + SD (n = 22) | 36.6 | 10.2 | 26.4 - 46.7 | 6.1 - 14.3 | < 0.001 | |
Disease controlled during follow-up (yes/no)b | 38.5 | 14.2 | 27.1 - 39.7 | 9.4 - 18.9 | 0.002 |
Survival (from first diagnosis, first diagnosis of liver metastases, first interventional treatment of LMBC) estimated according to the Kaplan-Meier method. Factors found to have an independent impact on survival in the multivariate model (Table 5) were used as stratifying variables in a Kaplan-Meier analysis of survival after first interventional LMBC treatment. The log rank test was used for survival comparison
aAddressing overall survival data and significant influencing factors from multivariate cox regression
bPatients demonstrating either overall objective response, stable disease, or limited disease progression amenable to repeat local ablation were regarded as having controlled disease. Disease progression not amenable to local intervention was defined as non-controlled